StockNews.AI
ALT
StockNews.AI
36 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT

1. Pomerantz LLP is investigating Altimmune for potential securities fraud. 2. Altimmune's stock dropped 53.18% after an inconclusive trial result announcement. 3. The Phase 2b trial showed positive but not statistically significant findings. 4. Investors are encouraged to contact Pomerantz regarding class action participation. 5. Pomerantz specializes in corporate and securities class litigation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock price drop (53.18%) after trial results is alarming, indicating severe investor concern. Historically, substantial drops often foreshadow ongoing volatility and deeper scrutiny, leading to potential further declines.

How important is it?

The investigation and stock price fall significantly impact investor confidence, indicating a heightened risk for ALT. Legal scrutiny can lead to volatility and potential further declines.

Why Short Term?

Immediate investor sentiment is likely to be negative, as ongoing investigations can lead to further price instability and legal repercussions. Similar cases show that ongoing investigations often keep stocks under pressure in the short term.

Related Companies

GILDAMGNVRTX
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Altimmune, Inc.  (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 26, 2025, Altimmune issued a press release announcing “topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).” Although Altimmune described the results as “positive,” the press release reported that “[t]he effects on fibrosis improvement without worsening of MASH in an ITT analysis”—a key efficacy endpoint—“were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant).”  On this news, Altimmune’s stock price fell $4.10 per share, or 53.18%, to close at $3.61 per share on June 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News